Studies on 2-(3-benzoylphenyl) propionic acid (Orudis). A double-blind cross-over trial in patients with rheumatoid arthritis and an assessment of its influence on hepatic drug-metabolizing enzymes.

Cathcart, B J; Vince, John; Gordon, Arnold J.; Bell, M A; Chalmers, Ian

doi:10.1136/ard.32.1.62

Cited by 32 publications

(10 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our experience with the paired design reported here, however, contrasts markedly with these favourable results; we were unable to document a beneficial response, either biochemically or virologically. As an NSAID, ketoprofen has a chemical structure different from indomethacin (13). Although our study failed to demonstrate a beneficial response to ketoprofen, we cannot exclude the possibility that other NSAIDs in combination with IFN may be of value.…”

Section: Discussionmentioning

confidence: 55%

Failure of Ketoprofen and Interferon Combination Therapy to Improve Interferon‐Resistant Chronic Hepatitis C

Anderson

Zeng²,

Yoshida³

et al. 1997

Canadian Journal of Gastroenterology and Hepatology

View full text Add to dashboard Cite

FH Anderson, L Zeng, EM Yoshida, NR Rock. Failure of ketoprofen and interferon combination therapy to improve interferon-resistant chronic hepatitis C. Can J Gastroenterol 1997;11(4):294-297. Preliminary reports suggest that patients with interferon (IFN)-resistant chronic hepatitis C respond better to a combination of IFN-a and nonsteroidal anti-inflammatory drugs than to IFN alone. The efficacy of IFN combined with ketoprofen in the treatment of patients with IFN-resistant chronic hepatitis C was evaluated. Seventeen patients, nonresponsive after at least six months of treatment with IFN-a2b and subsequently treated with the combination of IFN-a2b plus ketoprofen for four months, were studied. Serum aminotransferases (alanine aminotransferase [ALT] and aspartate aminotransferase [AST]) and serum hepatitis C virus (HCV) RNA were analyzed before and throughout treatment. No patient normalized serum aminotransferases after combination therapy. There were no significant differences in mean serum ALT and AST levels before and after ketoprofen intervention. Serum HCV RNA became undetectable after treatment in only one patient, but was detectable again three months after treatment cessation. These results provide no convincing evidence that the combination of IFN-a2b with ketoprofen improves the response to IFN in patients nonresponsive to IFN alone. ) et l'ARN sérique du virus de l'hépatite C (HCV) ont été analysés avant, puis tout au long du traitement. Les aminotransférases sériques ne se sont normalisées chez aucun des patients après le traitement associatif. Aucune différence significative n'a été notée quant aux taux sériques moyens d'ALT et d'AST avant et après l'administration de kétoprofène. L'ARN du HCV sérique est devenu indécelable après le traitement chez un seul patient, mais était à nouveau décelable trois mois après la fin du traitement. Ces résultats n'offrent aucune preuve concluante que le traitement associatif IFN-a2b et kétoprofène améliore la réponse à l'IFN chez les patients qui ne répondent pas à l'IFN seul. Gastroenterology, Department of Medicine, University of British Columbia, Vancouver, British Columbia Correspondence and reprints: Dr Frank H Anderson, Vancouver Hospital & Health Sciences Centre, Room 206, 700 West 10th Avenue, Vancouver, Received for publication October 24, 1996. Accepted February 6, 1997 HEPATOLOGY O ver the past few years interferon (IFN)-alpha has been widely used to treat chronic infection with hepatitis C virus (HCV). A short term response, however, is seen in only approximately 40% to 50% of treated patients (1,2), and the percentage of patients achieving a long term response is significantly less. In a recent multicentre study only 22% of patients treated with IFN for 18 months were able to maintain a long term response, as reflected by normal serum aminotransferase, more than 18 months after discontinuing therapy (2). To improve the efficacy of IFN therapy, numerous strategies employing adjuvant therapy have been proposed. Medications such as ursodeoxycholic a...

show abstract

Section: Discussionmentioning

confidence: 55%

Failure of Ketoprofen and Interferon Combination Therapy to Improve Interferon‐Resistant Chronic Hepatitis C

Anderson

Zeng²,

Yoshida³

et al. 1997

Canadian Journal of Gastroenterology and Hepatology

View full text Add to dashboard Cite

show abstract

“…Ketoprofen has been shown to have no effect on hepatic drugmetabolizing enzymes, based on a study of plasma-clearance of antipyrine (Cathcart et al, 1973), and is unlikely therefore to interact with drugs metabolized by the liver.…”

Section: Discussionmentioning

confidence: 99%

“…In double-blind cross-over studies ketoprofen has been found to have significant analgesic and anti-inflammatory activity compared with placebo (Cathcart et al, 1973;Zutshi et al, 1973), and to have comparable therapeutic efficacy with indomethacin when given in equal dosage (Gyory et al, 1972) in patients with rheumatoid arthritis and osteoarthrosis of the hip.…”

Section: Introductionmentioning

confidence: 99%

Double-blind Cross-over Study of Ketoprofen and Ibuprofen in Management of Rheumatoid Arthritis

Mills¹,

Bloch²,

Bruckner³

1973

BMJ

View full text Add to dashboard Cite

SummaryA double-blind cross-over study of ketoprofen (Orudis) 150 mg daily and ibuprofen (Brufen) 1,200 mg daily was carried out in 35 outpatients with rheumatoid arthritis. Results suggest that analgesic and anti-inflammatory activity of ketoprofen is superior to that of ibuprofen. Significantly greater pain relief (P < 0 05) and reduction in joint circumference (P <0-01) was obtained with ketoprofen than with ibuprofen. Side effects of the drugs were comparable and pot serious.

show abstract

“…Ketoprofen (3-benzoyl--methylbenzeneacetic acid, Figure 1) is a nonsteroidal anti-inflammatory drug (NSAID), widely used in medicine as an analgesic and an antipyretic, mainly for the treatment of rheumatoid arthritis, osteoarthritism and ankylosis spondylitis, [1][2][3] but also for nonrheumatoid diseases. 4 Although the therapeutic action of ketoprofen is known to be mainly associated with inhibition of prostaglandin and leukotrien synthesis, 5 the mechanisms underlying this activity are still poorly understood and have been the subject of vigorous research.…”

Section: Introductionmentioning

confidence: 99%

Drug–excipient interactions in ketoprofen: A vibrational spectroscopy study

2006

View full text Add to dashboard Cite

Ketoprofen (3-benzoyl-a-methylbenzeneacetic acid) is a widely used nonsteroidal antiinflammatory drug (NSAID), always administered in the form of drug-excipient physical mixtures (PMs). The occurrence of possible interactions between ketoprofen and two commonly used excipients-lactose (LAC) and polyvinylpyrrolidone (PVP)-was evaluated, through vibrational spectroscopy techniques [both Raman and Inelastic Neutron Scattering (INS)]. Spectral evidence of drug:excipient close contacts, which were enhanced by aging, was verified for the (1:1) (w:w) (ketoprofen:PVP) and (ketoprofen:LAC) PMs, both by Raman and INS. These interactions were found to involve mainly the central carbonyl and the terminal methyl-carboxylic moieties of the ketoprofen molecule, this being reflected in particular vibrational modes, such as the methyl torsion, the outof-plane CÀ ÀOH bending, and the inter-ring C¼ ¼O stretching. #

show abstract

Studies on 2-(3-benzoylphenyl) propionic acid (Orudis). A double-blind cross-over trial in patients with rheumatoid arthritis and an assessment of its influence on hepatic drug-metabolizing enzymes.

Cited by 32 publications

References 14 publications

Failure of Ketoprofen and Interferon Combination Therapy to Improve Interferon‐Resistant Chronic Hepatitis C

Failure of Ketoprofen and Interferon Combination Therapy to Improve Interferon‐Resistant Chronic Hepatitis C

Double-blind Cross-over Study of Ketoprofen and Ibuprofen in Management of Rheumatoid Arthritis

Drug–excipient interactions in ketoprofen: A vibrational spectroscopy study

Contact Info

Product

Resources

About